Metformin, which demonstrated browning in rats [44], showed no effect on the amount of BAT in humans (women with polycystic ovary syndrome [45] and patients with metabolic syndrome combined with human immunodeficiency virus); GLP1 receptor agonists promote weight loss and improve all the cardiometabolic parameters studied by us (glucose, lipids, BP) through several alternative mechanisms. This evidence concerns the gene GLP1R and polycystic ovary syndrome.